About Us Resources Papers Brochures Infographics Posters Papers Videos & Webinars Plasmid Finder PAPERS A selection of flyers with data and highlights of some of our services and technologies at OXGENE Easy to digest data and information on our technologies and solutions at OXGENE This is our library of scientific posters that has been carefully created and curated by our amazing scientists at OXGENE This is our library of published papers from our select staff at OXGENE View our curated collection of videos and past webinars Overcoming the Challenges of Large Scale Plasmid Production - EBR OXGENE Sponsored/European Biopharmaceutical Review /25 May 2022 Gene therapy is one of the most exciting fields of biopharma today, but plasmids pose serious challenges for innovation and drug development. WuXi’s acquisition of OXGENE means a fusion of expertise, helping to create an efficient means of developing plasmids on a large... Meet TESSA: a new standard in viral vector manufacturing OXGENE Sponsored/Nature Communications /13 May 2022 A new transfection-free helper system supports a high-yield manufacturing process for recombinant adeno-associated viruses (rAAV), raising the bar for producing safe, high-quality viral vectors at scale. To learn more about TESSA, evaluate it or discuss partnering to... Future Technologies for Cell and Gene Therapy Manufacturing OXGENE Sponsored/GEN /11 May 2022/Issue Vol 42, No. 5 The concept of gene therapy arose initially during the 1960s and early 1970s. Turning that concept into a therapeutic reality has taken a tremendous amount of scientific discovery and pioneering manufacturing efforts. Today, nearly half a century later, gene and cell... Overcoming the Challenges of Large Scale Plasmid Production Katie Roberts Sponsored/International Biopharmaceutical Industry/14 April 2022/Issue Volume 5, Issue 1 Gene therapy involves inserting a new section of DNA into a patient’s cells, often encoding a healthy gene to replace a disease-causing copy. This DNA is delivered by viral vectors which are usually built from plasmids. Plasmids are small sections of genetic material which... Plasmids: How to Solve a Bottleneck in Scalable Gene Therapy Manufacturing? OXGENE Sponsored/Labiotech/26 October 2021 As gene therapies become increasingly successful, companies are in a competitive race to deliver manufacturing technologies that can streamline large-scale production at reduced costs and faster turnaround times. However, plasmids, the building blocks of viral vectors,... Breaking The Gene Therapy Bottlenecks OXGENE Editorial /Pharma Intelligence /02 October 2021 Insights into how to overcome common hurdles to manufacturing and developing gene therapy, including overcoming a reliance on plasmid technology, streamlining manufacturing processing, and more. Accelerating the Clinical Success of Gene Therapies through Viral Vector Engineering OXGENE Sponsored/GEN /01 September 2021/Issue Issuer Vol. 41, Issue 9 Viruses have evolved to invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genomes. While these properties make viruses dangerous pathogens, they also make them ideal couriers for getting new DNA into a host cell... Viral vector engineering to improve clinical performance and accelerate timelines for novel gene therapies Sophie Lutter Editorial /Manufacturing Chemist /13 August 2021 Viruses invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genome. This makes them dangerous pathogens as well as ideal couriers to transport new DNA into a host cell and ensure that it’s transcribed, reports Dr... Viral vector engineering to improve clinical performance & accelerate timelines for novel therapies OXGENE Editorial/Manufacturing Chemist/13 August 2021 Advanced therapy manufacturers have taken the head start that Nature’s given them and used developments in genetic engineering, computational biology and bioinformatics to perfect the viral particle as a vector for therapeutic DNA and hasten the clinical success of... Revving the engine of CAR-T development Sophie Lutter White Paper/TheScientist/14 July 2021 CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the barrier of solid tumours, taking imaginative approaches to overcome the numerous... 123